This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
HeartFlow’s Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronaryarteries, aiding risk assessment of coronaryarterydisease. F.A.C.C. “The
a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT) code beginning January 1, 2024. milla1cf Tue, 01/23/2024 - 13:44 January 23, 2024 — HeartFlow, Inc. ,
Here is an overview of sessions, events and meetings coordinated to help members in particular specialties, sections and areas of interest learn and engage with peers and expert cardiology professionals to advance their practice, patientcare and careers. 24 Education Sessions Symposiums at ACC The “Symposiums at ACC.24”
In its announcement about the workbook, ACC noted that cardiologists use digital devices and wearable technology to remotely monitor their patients for a variety of chronic cardiovascular diseases, including heart failure, coronaryarterydisease, vascular disease and atrial fibrillation.
GE HealthCare expects to integrate MIM Software solutions into its advanced visualization offerings to facilitate AI-based segmentation and contouring as well as dosimetry analysis for patients across their treatment journeys and in the growing fields of radiology, molecular imaging, and radiation oncology. “We
Cardiovascular CT's non-invasive nature allows patients to avoid being admitted to a hospital for imaging, which makes it more convenient and patient-friendly. Invasive catheterizations, commonly employed, may fall short in identifying obstructions that prior CT imaging of the coronaries can catch.
is the upgraded version of Nanox.AI’s cardiac solution, HealthCCSng, which has already shown tangible results in several healthcare systems, identifying patients at high risk of coronaryarterydisease while driving significant revenue to cardiology departments. HealthCCSng V2.0 For more information, please visit [link].
The new FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronaryarterydisease and cardio-oncology issues in seconds.
"This study highlights the power of our cell mimic platform in driving next-generation tests that could enhance patientcare." Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronaryarterydiseasepatients, particularly after coronary stenting.
Members of the Society of Cardiovascular Computed Tomography (SCCT) Health Policy & Practice Committee (HPPC) presented as subject matter experts during a May 2023 MAC-led Multijurisdictional Meeting on CAC Non-Invasive Technology for CoronaryArtery Plaque Analysis and later provided comments on the draft LCDs that helped shape the final policies.
Interventional cardiology has dramatically evolved over the past decades, introducing advanced techniques and tools that have revolutionized the treatment of coronaryarterydisease, valvular disorders, and structural heart diseases.
The Role of Cardiologists Cardiologists are at the forefront of the battle against heart diseases. Their expertise covers a wide range of cardiovascular conditions, including coronaryarterydisease, heart failure, arrhythmias, and congenital heart defects.
Compared to the reference group, patients with AIS alone and patients with concurrent CAD and AIS had higher MI risk (hazard ratio [HR] 4.91, 95% CI 4.63-5.21, 2.73, P = 0.04, respectively), while patients with CAD alone had no elevated risk (HR 1.17, 95% CI 0.66-2.06, 5.21, P < 0.001; HR 1.67, 95% CI 1.02-2.73,
These technologies are reshaping how cardiology practices manage operations, deliver care, and enhance patient outcomes. This blog explores the profound benefits of AI and machine learning, which are revolutionizing cardiology practices, enhancing efficiency, and ultimately improving patientcare.
I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronaryarterydisease, we expect to see this trend really impact the way CT is used in the future.” This interdisciplinary approach is consistently contributing to more effective patientcare.
Interventional cardiology has dramatically evolved over the past decades, introducing advanced techniques and tools that have revolutionized the treatment of coronaryarterydisease, valvular disorders, and structural heart diseases.
By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patientcare. The advances lead to better patientcare with accurate diagnosis and treatment. Alternatively, it also helps enhance arrhythmia management with coronaryarterydisease.
September 2024 Approvals Flurpiridaz F 18 Approval Date: September 27, 2024 Indication: A radioactive positron emission tomography (PET) tracer for imaging myocardial ischemia and infarction in adults with suspected or known coronaryarterydisease. To explore FDA approvals from January to July 2024, click here.
allows clinicians to focus on what truly matters providing exceptional patientcare. These measurements are used to assess the severity of coronaryarterydisease. AltiX AI.i By automating routine tasks and streamlining workflow, AltiX AI.i Cardiac Catheterization The AltiX AI.i
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content